CRSPNEUTRAL

Revenue Growth (YoY)

68.6%

Higher than 98% of Healthcare sector peers

Updated 1078h ago

Sector Performance

98th percentile

CRSP

68.6%

Sector Median

6.2%

Sector Avg

3.8%

📊

Deep Analysis

CRISPR Therapeutics’ revenue growth (year-over-year, or YoY) of 68.6% means the company generated 68.6% more revenue in the most recent quarter compared to the same quarter one year ago.

Within the Healthcare sector, the median revenue growth is 6.2%, placing CRISPR in the 98th percentile among sector peers — far above the typical company. The trend analysis is limited: the year-over-year change and quarter-over-quarter change are both listed as N/A, and only a single historical value of 68.6% is available, so no directional pattern can be assessed. The combination of an exceptionally high revenue growth level with no trend data creates a mixed picture — the strong growth signals a positive opportunity, but the absence of a confirmed trend increases uncertainty about sustainability. This metric supports the overall NEUTRAL verdict because the standout level of growth is offset by insufficient information to gauge momentum, making a cautious stance appropriate.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about CRSP?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does CRSP's Revenue Growth (YoY) compare to its sector?

CRSP's Revenue Growth (YoY) of 68.6% compares to a Healthcare sector median of 6.2%, placing it in the 98th percentile.

Who are CRSP's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: AMGN (5.8%), CPRX (5.6%), HIMS (3.8%), BAX (2.9%), BMY (2.6%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.